Non-steroidal anti-infl ammatory drugs (NSAIDs) have been documented in animal and human studies to reduce risk for colorectal cancer and adenomatous polyps, but risk modifi cation for subgroups of the population and effects on hyperplastic polyps have been less studied.
INTRODUCTION
Laboratory, epidemiologic, and clinical trial research support the premise that non-selective non-steroidal anti-infl ammatory drugs (NSAIDs) such as aspirin and ibuprofen have a chemopreventive eff ect against colorectal cancer ( 1 -15 ) . NSAIDs have also been shown to be inversely related with the incidence and recurrence of colorectal polyps, established precursors of colorectal cancer ( 2 -4,9,13,16 -19 ) . Non-selective NSAIDs inhibit the activity of both cyclooxygenase-1 (COX-1) and COX-2, with aspirin preferentially inhibiting COX-1 activity at normal doses ( 6 ) and ibuprofen targeting both COX enzymes ( 20 ) . Th e most widely recognized mechanism to explain the chemopreventative eff ects of NSAIDs on colorectal polyp development relates to the anti-infl ammatory properties of NSAIDs. Specifi cally, the inhibition of COX activity leads to downregulation of the synthesis of prostaglandins, lipids that have a pivotal role in the development of the infl ammatory response ( 5, 8, 21, 22 ) . However, there is also evidence to suggest that NSAIDs have pro-apoptotic properties, suppress angiogenesis, and operate through additional mechanisms that are cyclooxygenase independent ( 1,5 -9,22 -26 ) .
As NSAIDS also have adverse aff ects, such as increased risk of gastric ulcer perforation and upper gastrointestinal bleeding, it is recognized that any chemopreventative recommendations associated with NSAID use will need to be tailored by individual costbenefi t assessment ( 3, 24 ) . However, few studies of the association of NSAID use and colorectal polyps in a general risk population undergoing colonic examination under highly controlled circumstances have been large enough to allow for the consideration of risk subgroups such as sex, age (especially older age), and body mass index (BMI) characteristics. Further, less data have been available concerning the association of NSAIDs with risk of hyperplastic polyps, lesions that have been generally thought not to have malignant potential, but have been hypothesized to be related to one subtype of colorectal cancer ( 27 ) . Th e analyses presented here use data generated by the 56,175 men and women undergoing fl exible sigmoidoscopy screening examinations between September 1993 and September 2000 as part of the baseline intervention in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Using a cross-sectional design, we investigated the relationship between recent use of the most commonly ingested NSAIDs, aspirin and ibuprofen, among population subgroups of the PLCO screened participants, and risk for polyp prevalence by histotype.
METHODS

Study population
Men and women 55 to 74 years of age were recruited to the PLCO Cancer Screening Trial beginning in 1993. Th is large trial, designed to test the eff ectiveness of screening procedures for these four cancers, is being conducted at 10 centers located throughout the United States (Birmingham, AL; Denver, CO; Detroit, MI; Honolulu, HI; Marshfi eld, WI; Minneapolis, MN; Pittsburgh, PA; Salt Lake City, UT; St Louis, MO; and Washington, DC). Th e study was approved by the Institutional Review Boards of the NCI and all 10 centers, initially in 1991 and continuing to date, and written informed consent was obtained from each participant.
To be eligible for the trial, subjects must have been 55 -74 years of age, have the ability to sign the consent form, not be undergoing treatment for cancer (excluding non-melanoma skin), have no history of cancer of the sites involved in the trial, no history of surgical removal of the prostate, colon or one lung, no current participation in another cancer screening or primary prevention trial, no use of Finasteride in the previous 6 months, and beginning in April 1995, no PSA test, colonoscopy, sigmoidoscopy, or barium enema in the previous 3 years. Aft er recruitment, subjects completed a baseline risk factor survey that included questions on usual use of aspirin and ibuprofen in the previous year as well as sociodemographic, lifestyle, and medical history variables. At study entry, individuals in the intervention arm received a fl exible sigmoidoscopic visualization of the distal colon (left side) up to 60 cm, which did not include removal of any detected lesions, but visualized polyps (up to 4) were documented. Participants who completed a sigmoidoscopic examination with results classifi ed as " abnormal suspicious " (evidence of possible neoplasia such as polyp or mass) were advised to obtain further medical follow-up, which oft en entailed a colonoscopy ( 28 ) . All available clinical and pathological reports regarding lesions removed during diagnostic and related surgical procedures were reviewed and coded by trained medical record abstractors.
Data were retrieved for these analyses on 14 March 2003 for those recruited and undergoing baseline screening from September 1993 through September 2000. Among the randomized participants, 56,175 had undergone an initial successful sigmoidoscopic screening examination (insertion to at least 50 cm with > 90 % of mucosa visible or a suspect lesion identifi ed), described in detail elsewhere ( 28 ) . Of these, 56,081 (99.8 % ) had completed the baseline risk factor questionnaire. We excluded 6,895 (12.3 % ) of these participants because they had a self-reported history of one or more of these selected conditions: colorectal polyps ( n = 3,997), ulcerative colitis ( n = 722), Crohn ' s disease ( n = 220), familial polyposis ( n = 168), Gardner ' s syndrome ( n = 133), or a history of non-PLCO cancer other than non-melanoma skin cancer ( n = 2,556), leaving 49,186 subjects in our base population.
As the fl exible sigmoidoscopy procedure only examines the left side of the colon (descending colon, sigmoid colon, and rectum), we restricted our case group to polyps (adenomas or hyperplastic polyps) confi rmed by follow-up in these locations. We did not include polyps found in other locations in the colon as examination of the remainder of the colon was not done for the control group. Subjects with left -sided invasive colon cancer or benign lesions not classifi ed as polyps diagnosed as a consequence of baseline screening were excluded from these analyses, as were subjects with no evidence of adequate follow-up of abnormal suspicious fi ndings in the subsequent 12 months or with pending results ( n = 4,738; 9.6 % ). Subjects for which a benign polyp or a polyp with highgrade dysplasia was found but the location was undetermined were also excluded ( n = 209; 0.4 % ).
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All cases included in this study had a positive result on the screening examination followed by histological verifi cation of colorectal polyps in the distal colon ( n = 5,663). Th e cases were subclassifi ed into subjects with hyperplastic polyps only ( n = 1,646) and subjects with at least one adenoma, including cases with concurrent hyperplastic polyps ( n = 4,017). Th e adenoma group was further classifi ed into those with at least one advanced adenoma ( n = 1,571), defi ned as large ( > 1 cm), having villous elements (including villous or tubulo-villous adenoma), or having high-grade dysplasia (carcinoma in situ ). Controls were those individuals ( n = 38,396) who screened negative for polyps of the distal colon ( n = 36,635) or screened positive but were found on follow-up diagnostic examination not to have polyps of the distal colon ( n = 1,761).
Exposure ascertainment
Two separate questions on the baseline survey asked whether participants regularly used aspirin and aspirin-containing products (e.g., Bayer, Buff erin, or Anacin) and / or ibuprofen and ibuprofencontaining products (Advil, Nuprin, or Motrin) in the 12 months prior to screening. Regular users of either products were asked to report the frequency of use of aspirin and / or ibuprofen in two additional questions, with the eight following possible response categories: no regular use, < 2 / month, 2 -3 / month, 1 / week, 2 / week, 3 -4 / week, 1 / day, and ≥ 2 / day. To categorize the frequency of medication use, we converted the responses for each drug into a frequency of pills per month, assuming 30 days and 4 weeks / month. Four frequency categories for aspirin, for ibuprofen and for the two combined, were defi ned based on the number of pills per month, which also refl ect commonly prescribed doses: < 4 / month (irregular use), ≥ 4 to 29 / month (low use), 30 -59 / month (moderate use), and ≥ 60 / month (heavy use). For the calculation of trend tests across the use categories, we treated the four-level NSAID dose variables as a continuous variable in the model, with each level represented by the mean value of that category (e.g., 0, 17, 45, and 105).
Statistical analysis
Adjusted odds ratios (ORs) and 95 % confi dence intervals (CIs) relating prevalence of left -sided adenomas, by histological category, to aspirin and ibuprofen use individually were calculated comparing regular use and the dose categories for each drug to the referent category of no or irregular use. Th e ORs and CIs were estimated using multivariable logistic regression and included the following potential confounding variables that are either established colorectal cancer risk factors, or have been associated with use of NSAIDs: sex, age group (55 -59 / 60 -64 / 65 -69 / 70 -74), race / ethnicity (White / Black / Hispanic / Other), smoking (never / ever), physical activity level (none / < 1 h / week / 1 -2 h / week / ≥ 3 h / week), BMI ( < 25 kg / m 2 / 25 -< 30 kg / m 2 / ≥ 30 kg / m 2 ), and history of cardiovascular disease (i.e., coronary heart disease, heart attack, stroke, or hypertension) and arthritis (due to common use of NSAIDs for these conditions), as well as history of osteoporosis and screening center. A variable remained in the fi nal model if its inclusion in models with NSAIDs and a polyp category resulted in a change in the risk estimate that was > 10 % . For analyses restricted to females, we adjusted for hormone therapy (HT) (ever / never). Adjustment for history of osteoporosis and HT (for females only) resulted in a change in risk estimate that was > 10 % , so we included these variables in the models. Several dietary variables that have been associated with colorectal neoplasia (fi ber, calcium, and folate intake) did not materially change the risk estimates (defi ned as a > 10 % change in the β coeffi cient), so they were not included in the fi nal multivariable models.
Statistical signifi cance of multiplicative interactions between NSAID use and selected variables (sex, age, HT use, BMI, race, smoking, history of cardiovascular disease, history of arthritis, and history of osteoporosis) in relationship to the outcomes of interest were evaluated using the Wald test for interaction in the logistic regression models. Analyses were repeated with stratifi cation by sex, age, BMI, and HT use.
RESULTS
NSAID use among study participants
Among controls ( n = 38,396), 50 % were irregular users of NSAIDs, 31 % reported regular use of aspirin (only), 10.5 % used ibuprofen (only), and 8 % reported regular use of both ( Table 1 ) . Slightly more men (52 % ) than women (48 % ) reported use of NSAIDs. NSAID use was most frequent in controls who were white, older, heavier, and had a history of tobacco use. Subjects with a reported history of cardiovascular disease or arthritis tended to be more frequent users of these NSAIDs, at 61 % and 57 % , respectively.
NSAIDs and polyp histotype
Regular use of aspirin only was inversely associated with hyperplastic polyps (OR = 0.8, 95 % CI = 0.7 -0.9), adenomatous polyps (OR = 0.8, 95 % CI = 0.8 -0.9), and advanced adenomas (OR = 0.8, 95 % CI = 0.7 -0.9) ( Table 2 ) . A similar and borderline statistically signifi cant pattern was seen for regular use of ibuprofen only and advanced adenomas (OR = 0.8, 95 % CI = 0.6 -1.0). Regular use of both aspirin and ibuprofen was also associated with lower polyp prevalence: hyperplastic polyps (OR = 0.7, 95 % CI = 0.6 -0.9); adenomatous polyps (OR = 0.8, 95 % CI = 0.7 -0.9), and advanced adenomas (OR = 0.8, 95 % CI = 0.7 -1.0). Dose-response relationships were noted for hyperplastic polyps and adenomas (total and advanced), with respect to frequency of use for aspirin only and aspirin / ibuprofen combined ( P < 0.0004 for all trends). Frequency of ibuprofen use alone showed a dose-response trend for risk of any adenomas ( P for trend < 0.01). Th ere were no statistical diff erences in these risk estimates by polyp histological aggressiveness category, and no diff erences when considering polyp size ( < 1 vs. ≥ 1 cm), or multiplicity (1 vs. 2 + ) (data not shown). Th e inverse associations between use of NSAIDs and polyp prevalence did not diff er according to location of the lesion ( Table 3 ).
NSAIDs and polyps by risk subgroups
Dose-response trends were evident for men only ( Table 3 ; P < 0.005 for all trends), for whom 30 -40 % risk reductions were found among men using NSAIDs with the highest frequency, whereas no clear associations were noted in women (interaction
COLON/SMALL BOWEL
NSAIDs and Left-Sided Colorectal Polyps
by sex for aspirin use only, P = 0.02; for ibuprofen only, P = 0.16; and for combined, P = 0.006; data not shown).
We also evaluated NSAIDs use and risk for adenomas, stratifying by age group and BMI ( Table 3 ) . Th e inverse association of NSAID use with colorectal adenomas was stronger among individuals aged 70 -74 years compared with those aged 55 -69 years, such as an OR = 0.5 (95 % CI = 0.4 -0.8) for > 60 NSAIDs per month compared with an OR = 0.8 (95 % CI = 0.7 -0.9) in the younger group. However, the trends for stronger inverse associations with increased frequency of NSAID use were statistically signifi cant for both age group strata.
Similarly, we observed a slightly more pronounced protection of NSAIDs for individuals with BMI < 25 than overweight (BMI ≥ 25) individuals; for example, ORs for regular use of both aspirin and (5) 863 (50) 454 (26) 238 (14) 170 (10) a Missing data for race / ethnicity (16 subjects), body mass index (383 subjects), smoking history (16 subjects), physical activity (3,668 subjects), disease history (cardiovascular disease 393 subjects, osteoporosis 1,213 subjects, arthritis 690 subjects, diabetes 1,037 subjects), and regular use of aspirin and ibuprofen (14 subjects). b " No regular use " was defi ned by subjects ' responses to a question about whether they regularly used aspirin, ibuprofen, or products containing these compounds. c Hypertension, coronary heart disease / heart attack, and stroke.
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the females, we also analyzed NSAID use by BMI and HT (ever vs. never), as HT has been shown to be protective for colon cancer and colon polyps in this and other populations ( 29 -32 ) . A protective eff ect for regular NSAID use and all adenomas remained only in low-normal BMI (OR = 0.8, 95 % CI = 0.7 -1.0) but not overweight women, and was observed across both categories of HT use (data not shown).
DISCUSSION
Our analyses confi rm results from previous studies that habitual use of non-selective NSAIDs is associated with a decreased risk of adenomatous polyps. Our risk estimates fall within the same range of the previous studies ( 2,4,5,9 -11,15,19,33 -35 ) . Consistent with other reports, the protective association for polyps is present in the rectum and colon, as has also been found for colorectal ibuprofen were 0.6 (95 % CI = 0.4 -0.8) for BMI < 25 and 0.9 (95 % CI = 0.7 -1.0) for BMI ≥ 25, although the trends for stronger inverse associations with increased frequency of NSAID use were not signifi cantly diff erent among the two BMI groups. Although the estimates were imprecise, protective ORs for use of aspirin, and increasing use of aspirin and ibuprofen combined, were evident in blacks as well as whites, with no interaction between NSAID use and race (data not shown). No statistical interactions were found between NSAIDs and adenomas related to other behavioral and medical history variables.
We further investigated the associations stratifying by both gender and BMI ( Table 4 ) and demonstrated that the inverse association between regular NSAID use and adenomas among females was observed only among the BMI < 25 group (OR = 0.8, 95 % CI = 0.7 -1.0) ( P for interaction = 0.04), whereas a similar magnitude of protection was found for males in both BMI groups. Among cancer ( 7, 12, 17, 19, 22, 36 ) , although some studies demonstrate more protection for the colon than rectum ( 14, 37 ) or the opposite ( 38 ) .
Notably, we found that aspirin was protective for hyperplastic polyps in addition to adenomas, supporting suggestive fi ndings from two other studies of hyperplastic lesions ( 39, 40 ) . Hyperplastic polyps have been considered of little interest for colon carcinogenesis, but there has been evidence that hyperplastic polyps may be precursors to some types of colorectal cancer, suggesting that at least a subset may be of clinical and public health interest ( 27 ).
Tangrea et al. ( 17 ) reported that a US study population, recruited between 1993 and 2000, were largely taking aspirin, and next, ibuprofen, supporting the premise that we captured the majority of NSAID use with our baseline survey questions directed toward the use of only these two drugs. Th e time period of our study predates the widespread use of COX-2 inhibitors, reducing concern that use of these drugs was not taken into account on the questionnaire ( 26 ) . Th e protective eff ects in our analyses appeared to be more consistently stronger for aspirin than ibuprofen, aligned Adjusted for center, sex, age, race / ethnicity, smoking, physical activity, body mass index, cardiovascular disease, osteoporosis, and arthritis, unless used as a stratifying variable; additionally adjusted for hormone replacement therapy among females. Total n in analyses vary slightly due to missing data for included variables. ( 12 ) showed that protection for advanced adenomas was more evident in females. Tangrea et al. ( 17 ) , in their analyses of data from the Polyp Prevention Trial, found that NSAIDs protected against the recurrence of polyps in both men and women. Diff erent disease and behavior patterns for men and women in the PLCO population could have contributed to our discrepant fi ndings; for example, if the PLCO women, on average, had not been using NSAIDs as long as the men. Perhaps a larger proportion of the women in these other studies were of normal weight compared with the women in the PLCO, which could account for some difference in fi ndings, although one other study found, in contrast to us, that NSAIDs have stronger inverse associations with adenomas in obese individuals ( 51 ) . Future work directed at clarifying these inconsistencies by sex need to consider menopausal status, HT use, BMI, and dose and duration of NSAID use in analyses. Th ere has been speculation that the inverse association of NSAIDs with adenomas wanes as age increases ( 7 ) . One study of the UK General Practice Research Database suggested a trend toward a stronger preventive association among persons < 70 years old ( 19 ) , and a clinical trial of aspirin and recurrent adenomas demonstrated a stronger inverse relationship for people less than the median age (57 years) ( 12 ) . When we stratifi ed by age, we found that in the oldest group of 70 -74 year olds, NSAID use imposed a higher relative decrease of risk in both males and females. Hoff meister et al. ( 52 ) concluded in their review that few studies have specifi cally considered NSAIDs and with fi ndings related to colon malignancies reported in a review by Harris et al. ( 11 ) , although many studies have not found diff erences in protection by these drugs for either colorectal adenomas or cancers ( 7, 15, 19, 26, 38 ) . Th ere are some diff erences in the eff ects of non-selective NSAIDs by dose and type; for example at lower doses, aspirin selectively inhibits COX-1 in platelets, whereas ibuprofen inhibits COX-1 and COX-2 to the same extent ( 6, 21 ) , and aspirin is the only NSAID that irreversibly modifi es the cyclooxygenase enzyme ( 41 ) . A caveat in our study is that the results for ibuprofen were less precise because fewer subjects used this drug on a consistent basis.
Use of aspirin and ibuprofen
Similar to our fi ndings, most studies have demonstrated stronger protective eff ects related to adenomas with more frequent use or higher doses of NSAIDs, including all but one ( 12 ) of recently reported randomized clinical trials ( 6, 13, 17, 19, 40, 42 ) . We also found the protective eff ects similar for all colorectal polyps including advanced adenomas, suggesting that NSAIDs could be contributing to the suppression of both early and late polyp progression. Although Garcia Rodriguez and Huerta-Alvarez ( 19 ) commented that NSAIDs appear to protect against the progression and growth of polyps rather than de novo formation, others believe that the greatest eff ects are on polyp initiation and early promotion ( 38, 43 ) . For colorectal cancer, there is general agreement among most long-term follow-up studies that protective eff ects from NSAIDs only become apparent aft er 6, 10, or 20 years ( 14, 15, 38 ) . Two notable long-term cohort studies, the Physician ' s Health Study and the Women ' s Health Study, did not show protective eff ects of aspirin use for colorectal cancer, but the doses used are not considered by many to be high enough ( 44, 45 ) .
Our results suggest that these associations between NSAIDs and polyps vary by sex, refl ecting what has been found for aspirin use related to prevention of cardiovascular outcomes ( 46, 47 ) . In our data, NSAIDs were most consistently protective in men. Whether these diff erences, if valid, are due to a combination of variations in anatomy and physiology, hormone milieu, pharmacodynamics, or pharmacogenomics remains to be explored ( 48 ) . Although most colorectal cancer in the elderly, and two of four studies that did include older people showed a risk reduction similar to that of other age groups; the review by Flossman and Rothwell et al. ( 15 ) concluded no diff erence of eff ect by age group. However, in a trial of a selective COX-2 inhibitor, the greatest suppression of adenomas and colorectal cancers was detected among subjects > 70 years old ( 53, 54 ) . Whether and how lifestyle and biologic changes related to aging (e.g., increased gene hypermethylation, decreased calcium absorption) contribute to agerelated modifi cation of NSAIDs protective action remains to be studied. Similar to our fi ndings, Sansbury et al. ( 55 ) found that the relationship between NSAIDs and in their case, colon cancer, was similar between African Americans and whites. Th e strength of these results lies in the large, geographically, and demographically diverse sample with a substantial number of cases and in the use of a standardized survey and screening protocol in which the entire population underwent a systematic examination of the left colon, allowing us to avoid detection bias, adjust for and consider eff ect modifi cation for many variables, and reduce the misclassifi cation of our outcome variables. We also used a more general risk population, rather than one at high risk due to a previous history of polyps or cancer, or having a genetic condition such as familial adenomatosis polyposis.
Th e study population consisted of people willing to participate in a prolonged and fairly demanding cancer screening trial, who are not representative of the general population ( 56, 57 ) . Th erefore, any characteristics of this volunteer population that might aff ect the relationship between NSAID use and polyps would reduce the generalizability of our fi ndings. Although our outcome variable of polyp prevalence was measured in a standardized manner, our independent variables, aspirin and ibuprofen use, relied on self-report using relatively crude questions that only queried about recent use. Our most severe limitation was that we did not collect data to assess duration of use or specifi c doses of medications used. An advantage to using this survey approach is that it captured the use of both prescription and over-the-counter use of these drugs.
Another limitation of our data is that we could only analyze polyps occurring on the left side of the colon as the screening study used fl exible sigmoidoscopy, not colonoscopy. Further, the study was cross-sectional and the outcome was prevalent rather than incident polyps; therefore, we cannot distinguish whether NSAIDs are related to the occurrence of new polyps or the progression of polyps or both. However, we will have opportunities in the PLCO to study incident adenomas, recurrent adenoma, and colon cancer. Blood DNA samples are also available to replicate fi ndings from others on polymorphisms that may modify the action of NSAIDs on colorectal adenomas ( 58 -62 ) .
NSAIDs as potential chemopreventive agents for colorectal polyps and cancer continue to be a source of both hope and controversy ( 25, 26, 53, 63, 64 ) . Although these drugs are eff ective, their deleterious side eff ects among some people are well described ( 54,65 -68 ) . Better characterization of individuals at high risk of sporadic colorectal cancer and for whom NSAIDs help reduce their risk without a high probability of serious medical consequences, and improved understanding of NSAIDs eff ects for other health outcomes, would help evaluate the cost benefi ts of NSAIDs on a public health scale.
